Medications for Urothelial Carcinoma

4 results

  • balversa - erdafitinib tablet, film coated

    (Erdafitinib)
    Janssen Products Lp
    BALVERSA treats adults with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations whose disease progressed after at least one prior systemic therapy. Patient selection requires an FDA-approved companion diagnostic. Not recommended for patients eligible for PD-1/PD-L1 inhibitor therapy who have not yet received it.
    Medication Details
    Drug Interactions

  • bavencio - avelumab injection, solution, concentrate

    (Avelumab)
    Emd Serono, Inc.
    Bavencio (avelumab) is a PD-L1 blocking antibody indicated for metastatic Merkel cell carcinoma (adults and patients 12+), locally advanced or metastatic urothelial carcinoma (maintenance after platinum chemotherapy or following progression on platinum chemotherapy), and advanced renal cell carcinoma (first-line, with axitinib).
    Medication Details
    Drug Interactions

  • keytruda - pembrolizumab injection, powder, lyophilized, for solution

    (Pembrolizumab)
    Merck Sharp & Dohme Llc
    KEYTRUDA is a PD-1 blocking antibody that treats multiple cancers—including melanoma, lung, head and neck, bladder, colorectal, gastric, cervical, breast, and renal cancers—as well as MSI-H/dMMR and TMB-H solid tumors, used across neoadjuvant, adjuvant, and metastatic settings.
    Medication Details
    Drug Interactions

  • opdivo - nivolumab injection

    (Nivolumab)
    E.R. Squibb & Sons, L.L.C.
    Opdivo is a PD-1 blocking antibody indicated for multiple cancers including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal cancer, and gastric cancers in adults and select pediatric patients.
    Medication Details
    Drug Interactions